Apotex is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $27.9B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Apotex's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Jun 2024 | $2.7B |
| Jakafi | Incyte | Generic | 2028 | In litigation | $3.1B |
| Descovy | Gilead | Generic | 2031 | Settled 2022 | $2.8B |
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
Company facts: Apotex. Each drug page lists sources for these entries. Brand sales show the size of the market, not Apotex's share of it.